Allergic Rhinoconjunctivitis
4
Pipeline Programs
4
Companies
4
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
2
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
4 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Stallergenes GreerSTALORAL® Birch 300 IR
Blueprint MedicinesBLU-808
RegeneronDupixent®
Faes FarmaBilastine
Clinical Trials (4)
Total enrollment: 718 patients across 4 trials
Safety and Efficacy of STALORAL® Birch 300 IR in a Paediatric Population With Birch Pollen-induced ARC w/o Asthma
Start: Sep 2023Est. completion: Aug 2025553 patients
Phase 3Completed
Study of BLU-808 in Allergic Rhinoconjunctivitis
Start: Apr 2025Est. completion: Sep 202521 patients
Phase 2Completed
Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction
Start: Nov 2020Est. completion: Feb 2025108 patients
Phase 2Completed
Pharmacokinetic Study of Bilastine in Children From 2 to < 12 Years of Age With Either Allergic Rhinoconjunctivitis (AR) or Chronic Urticaria (CU)
Start: Jan 2010Est. completion: Jun 201236 patients
Phase 1/2Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
4 companies competing in this space